Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03878069 · ClinicalTrials.gov registry record
Registry Study of Revcovi Treatment in Patients With ADA-SCID
A clinical trial, sponsored by Chiesi Farmaceutici S.p.A..
- Completed
- Registry status
- 32
- Enrollment target
NCT03878069 is a clinical trial that has completed, run by Chiesi Farmaceutici S.p.A.. The registered enrollment target is 32 participants.
The verdict
NCT03878069 has completed, sponsored by Chiesi Farmaceutici S.p.A..
- COMPLETED
- Registry status
- 32 participants
- Enrollment target
Study Summary
This registry study is being conducted in patients with adenosine deaminase severe combined immune deficiency (ADA-SCID) who require enzyme replacement therapy (ERT) treatment with Revcovi. Data on safety and on measures of efficacy are collected.
Interventions
- BIOLOGICAL elapegademase-lvlr
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2019-09-30 |
| Est. Completion | 2023-01-18 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03878069
The ClinicalTrials.gov registry entry for NCT03878069 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Chiesi Farmaceutici S.p.A., which has 30 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which elapegademase-lvlr is the first listed.
NCT03878069 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03878069 about?
NCT03878069 is a clinical study titled "Registry Study of Revcovi Treatment in Patients With ADA-SCID". This registry study is being conducted in patients with adenosine deaminase severe combined immune deficiency (ADA-SCID) who require enzyme replacement therapy (ERT) treatment with Revcovi. Data on safety and on measures of efficacy are collected.
What is the current status of trial NCT03878069?
This trial is currently completed. The enrollment target is 32 participants. The study started on 2019-09-30. Estimated completion is 2023-01-18.
What interventions are being tested in trial NCT03878069?
The interventions under investigation include: elapegademase-lvlr (BIOLOGICAL).
Who is sponsoring clinical trial NCT03878069?
This trial is sponsored by Chiesi Farmaceutici S.p.A., which has 30 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.